The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

NCT05928455 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Vaccine Reaction

Interventions

BIOLOGICAL: LYB001
BIOLOGICAL: CoronaVac

Sponsor

Guangzhou Patronus Biotech Co., Ltd.

Collaborators

[object Object]
[object Object]